Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2
The experimentally established mechanism targets of Pyrophosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | TPI1 | P60174 | 1/20 | 0.33 |
| ▸ | PGD | P52209 | 1/20 | 0.30 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrophosphoric Acid SCHEMBL19458367 | 1.00 | FDPS (0.67) | FDPSBLMTDP1CA4TPI1 | |
| Pyrophosphoric Acid SCHEMBL2407700 | 1.00 | FDPS (0.67) | FDPSBLMTDP1CA4TPI1 | |
| Pyrophosphoric Acid SCHEMBL8993614 | 1.00 | FDPS (0.67) | FDPSBLMTDP1CA4TPI1 | |
| Triphosphate SCHEMBL122712 | 0.88 | FDPS (0.50) | FDPSBLMTDP1CA4TPI1 | |
| Triphosphate SCHEMBL8023890 | 0.88 | FDPS (0.50) | FDPSBLMTDP1CA4TPI1 | |
| Guanidine SCHEMBL32685203 | 0.85 | FDPS (0.47) | FDPSBLMTDP1CA4TPI1 | |
| Pyrophosphoric Acid SCHEMBL19458364 | 0.83 | FDPS (0.53) | FDPSBLMTDP1CA4 | |
| Pyrophosphoric Acid SCHEMBL4147800 | 0.83 | TDP1 (0.71) | FDPSBLMTDP1CA4TPI1 | |
| Pyrophosphoric Acid SCHEMBL8416891 | 0.82 | FDPS (0.83) | FDPSBLMTDP1CA4TPI1 | |
| Pyrophosphoric Acid SCHEMBL10770702 | 0.82 | FDPS (0.83) | FDPSBLMTDP1CA4TPI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2338923-B1 | Polyurethane with a biocidal polyuric material as comonomer | OBERWALDER SEBASTIAN (DE) | 2017-10-18 | — | — | EP | claimed |
| US-20080029126-A1 | Compositions and methods for improved planarization of copper utilizing inorganic oxide abrasive | ROHM AND HAAS ELECTRONIC MATERIALS CMP HOLDINGS, INC. | 2008-02-07 | — | — | US | claimed |
| US-6971945-B2 | Multi-step polishing solution for chemical mechanical planarization | ROHM AND HAAS ELECTRONIC MATERIALS CMP HOLDINGS, INC. (US) | 2005-12-06 | — | — | US | claimed |
| US-20050194357-A1 | MULTI-STEP POLISHING SOLUTION FOR CHEMICAL MECHANICAL PLANARIZATION | ROHM AND HAAS ELECTRONIC MATERIALS CMP HOLDINGS, INC. | 2005-09-08 | — | — | US | claimed |
| EP-1548076-A1 | Compositions and methods for low downforce pressure polishing of copper | Rohm and Haas Electronic Materials CMP Holdings, Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| US-20050136671-A1 | Compositions and methods for low downforce pressure polishing of copper | ROHM AND HAAS ELECTRONIC MATERIALS CMP HOLDINGS, INC. | 2005-06-23 | — | — | US | claimed |
| CN-1191216-A | Process for synthesis of guanidine dihydrogen phosphate and guanidine hydrogen phosphate | UNIV DONGBEI FORESTRY (CN) | 1998-08-26 | — | — | CN | claimed |
| US-12505900-B2 | Integrated synthesis and analysis systems and methods of use thereof | PURDUE RESEARCH FOUNDATION (US) | 2025-12-23 | — | — | US | disclosed |
| US-12391929-B2 | Polymerase-nucleotide conjugates for sequencing by trapping | ELEMENT BIOSCIENCES, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| WO-2025074271-A1 | MYT1 INHIBITORS FOR THE TREATMENT OF CANCERS HARBORING REPLICATION STRESS MUTATIONS | REPARE THERAPEUTICS INC. (CA) | 2025-04-10 | — | — | WO | disclosed |
| US-20240168030-A1 | DIRECT FLUORESCENT GLYCAN LABELING | BIO TECHNE CORP (US) | 2024-05-23 | — | — | US | disclosed |
| CN-116731147-A | Method for preparing fucosylated and defucosylated forms of proteins | 豪夫迈·罗氏有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11723983-B2 | Conjugates of a glycoprotein or a glycan with a toxic payload | GLYKOS FINLAND OY (FI) | 2023-08-15 | — | — | US | disclosed |
| EP-0458901-B1 | INHIBITING TRANSFORMATION OF CELLS HAVING ELEVATED PURINE METABOLIC ENZYME ACTIVITY | MASSACHUSETTS INST TECHNOLOGY (US) | 1997-12-17 | — | — | EP | disclosed |
| EP-0758681-A2 | Inhibiting transformation of cells having elevated purine metabolic enzyme activity | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1997-02-19 | — | — | EP | disclosed |
| US-5218092-A | Stability | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-06-08 | — | — | US | disclosed |
| EP-0509540-A1 | Dye-fixing element | FUJI PHOTO FILM CO., LTD. (JP) | 1992-10-21 | — | — | EP | disclosed |
| EP-0458901-A1 | INHIBITING TRANSFORMATION OF CELLS HAVING ELEVATED PURINE METABOLIC ENZYME ACTIVITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1991-12-04 | — | — | EP | disclosed |
| WO-1990009192-A1 | INHIBITING TRANSFORMATION OF CELLS HAVING ELEVATED PURINE METABOLIC ENZYME ACTIVITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-08-23 | — | — | WO | disclosed |
| EP-0370205-A2 | Glycosylated polypeptides | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1990-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723983-B2 | Conjugates of a glycoprotein or a glycan with a toxic payload | FUT6, CD44, SIGLEC7 | FDPS 3536/4885BLM 3372/4885TDP1 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.